References
Ciceri F, Lupo-Stanghellini MT, Korthof ET. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplant. 2013;48:183–5.
Bacigalupo A. How I treat acquired aplastic anemia. Blood 2017;129:1428–36.
Scheinberg P, Wu CO, Scheinberg P, Weinstein B, Nunez O, Sloand EM, et al. A randomized trial of horse versus rabbit antithymocyte globulin in severe acquired aplastic anemia. Blood. 2010;116:LBA – 4 – LBA – 4.
Ciurea SO, Cao K, Fernadez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53:521–34.
Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129:30–7.
Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transpl. 2014;20:1711–6.
Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transpl. 2015;50:685–9.
Bachegowda LS, Shah MV, Veltri LW, Tanase A, Popat U, Anderlini P, et al. HLA-mismatched bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant. 2017;52:1347–8.
DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4:1770–9.
Yadav SP, Thakkar D, Chatterjee G, Kapoor R, Rastogi N. Upfront Haploidentical Stem Cell Transplant with Posttransplant Cyclophosphamide in Children with Severe Aplastic Anemia. J Pediatr Hematol Oncol. 2020;42:500.
Dang BN, De Oliveira S, Gray A, Bowles LV, Moore TB. Successful engraftment of haploidentical bone marrow with post-transplantation cyclophosphamide in patients with aplastic anemia. Pediatr Transpl. 2020;24:1–5.
Iftikhar R, Chaudhry QN, Mahmood SK, Ghafoor T, Shahbaz N, Khan MA, et al. A novel TBI free conditioning protocol for haploidentical transplant in acquired aplastic anemia: (FluCAB-Prime). Bone Marrow Transplant. 2021;56:2309–11.
Arcuri LJ, Nabhan SK, Cunha R, Nichele S, Ribeiro AAF, Fernandes JF, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after haploidentical donor hematopoietic stem cell transplantation with post-transplantation cyclophophamide for relapsed/refractory severe aplastic anemia. Biol Blood Marrow Transpl. 2020;26:2311–7.
Acknowledgements
This work required no support from any funding agency or pharmaceutical industry.
Author information
Authors and Affiliations
Contributions
HH and IS collected, analyzed, and interpreted data and wrote the manuscript. HH, RR, MA, EK, and AT provided clinical information from patients and edited the manuscript. All the authors contributed to clinical care, and edited and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hashem, H., Rihani, R., Shanap, M.A. et al. Novel conditioning regimen for upfront haploidentical hematopoietic cell transplantation in children with severe aplastic anemia and donor-specific anti-HLA antibodies. Bone Marrow Transplant 57, 304–305 (2022). https://doi.org/10.1038/s41409-021-01536-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-021-01536-y
- Springer Nature Limited